Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
Purple Biotech announced a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering tri-specific antibody constructs and methods of use for its CAPTN-3 platform. This is a material intellectual property milestone that strengthens the company's patent estate and competitive position in its core immunotherapy platform. While not a discrete event type like M&A or earnings, the patent allowance is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's IP protection and platform defensibility.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-02
The filing discloses completion of the acquisition of Zuccaro Technical Consulting LLC (ZTC) on August 31, 2026, pursuant to a Purchase Agreement dated June 23, 2026. Item 2.01 explicitly states "Completion of Acquisition or Disposition of Assets," and the press release emphasizes strategic benefits including expanded capabilities, established federal customer relationships, incremental revenue, and cross-selling opportunities across ROC's Vision AI platform. This is a material M&A completion event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-09-02
EX-99.1
This exhibit is a private placement subscription agreement for the issuance of ordinary shares under Regulation S, targeting approximately US$10,000,000 (3,968,254 shares) with a maximum of up to 5,952,381 shares at US$2.52 per share. The agreement explicitly states the shares are unregistered under the Securities Act and offered solely in reliance on a Regulation S exemption to non-U.S. persons. This is a classic dilutive equity issuance that would materially affect shareholder ownership and capitalization.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-02
EX-99.1
This is a press release announcing DDC Enterprise Limited's unaudited financial results for the first half of 2026, disclosing revenue of US$20.2 million (29% YoY growth), a net loss of US$38.4 million (driven by non-cash Bitcoin mark-to-market losses), and positive Adjusted EBITDA of US$1.2 million from core food operations. The exhibit includes full consolidated financial statements (income statement, balance sheet, and reconciliations) and is clearly a periodic earnings announcement, not a routine administrative disclosure. The results are material to investors assessing the registrant's operational performance and financial condition.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-02
EX-99.1
This press release announces the results of Yimutian's 2026 annual general meeting held on August 31, 2026, disclosing that three shareholder resolutions were adopted: (1) increasing Class B share voting rights from 20 to 1,000 votes per share, (2) increasing authorized share capital from US$200,000 to US$2,000,000 with substantially expanded share authorizations, and (3) amending and restating the company's Memorandum and Articles of Association. These are material governance and capital structure changes requiring shareholder approval, directly matching the shareholder_vote_results classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-02
Rhoniel A. Daguro resigned as Chief Executive Officer effective September 4, 2026, which is the principal disclosed action. Although the filing also discloses his appointment as Chairman and Thomas R. Szoke's appointment as Interim CEO, the central event is Daguro's departure from the CEO role. The filing explicitly states his resignation was accepted by the Board and constitutes "Good Reason" under his Retention Agreement, triggering severance and equity benefits. This is material to investors as it represents a change in executive leadership at a company that references "substantial doubt regarding the Company's ability to continue as a going concern."
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
Item 3.01
Eureka Acquisition Corp received written notice from Nasdaq on August 27, 2026 that it failed to meet two continued listing requirements: (1) the minimum 500,000 publicly held shares under Nasdaq Rule 5550(a)(4), and (2) the $35 million minimum market value of listed securities under Rule 5550(b)(2). While the notices are currently non-binding notifications of deficiency rather than imminent delisting orders, they establish a clear delisting risk with defined compliance periods (45 days for the public float rule and 180 days for the MVLS rule). The disclosure explicitly states "there can be no assurance that the Company will be able to regain or maintain compliance with the MVLS Rule," indicating material uncertainty about the company's continued listing status.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
This press release announces a strategic partnership between Eco Wave Power U.S. and AI engineering GmbH to develop a Digital Twin platform for wave energy systems. The agreement represents a material operational and strategic development—combining advanced simulation, machine learning, and real-world data to optimize the company's proprietary technology and support global scalability. While not a discrete M&A transaction, debt issuance, or other named event type, it is clearly a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's technology roadmap and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-02
EX-99.1
This press release announces that Luda Technology's subsidiary Shenzhen Mayi has secured a one-year sales contract with Beijing Dasan Supply Chain Management Company valued at approximately $17.8 million for supply of rebar, wire rod, and steel pipe fittings. The disclosure is a material operational/commercial milestone for the company's steel-products trading business, representing a significant contract that expands product offerings and demonstrates supply-chain capabilities. While not a discrete event type like M&A or earnings, it is a material business development that would affect a reasonable investor's assessment of the company's growth prospects and operational scale.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-02
EX-99.1
Can-Fite announced entry into a definitive agreement for immediate exercise of warrants to purchase 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, generating approximately $4.0 million in gross proceeds. In consideration, the company will issue new unregistered warrants to purchase 3,183,476 ADSs—a 2:1 warrant issuance that is dilutive to existing shareholders. The new warrants are offered in a private placement exempt from registration under the Securities Act, characteristic of a dilutive equity issuance.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-09-02
EX-99.1
This disclosure reports a material event in an ongoing tender offer by Holcim Ltd. for Cementos Pacasmayo's common shares. The selection of a valuation entity (MSRA S.A.C.) to determine the minimum price for the tender offer is a procedural step integral to the acquisition process. Tender offers and change-of-control transactions are core M&A activity that materially affect shareholders' interests and investment decisions.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-09-02
EX-99.1
This press release announces a 1-for-15 reverse stock split of Class A and Class B Ordinary Shares, effective September 8, 2026, following shareholder approval at an extraordinary general meeting on August 24, 2026. While a reverse stock split is a capital structure event with governance dimensions, it does not fit the specific event types (exec_departure, exec_appointment, exec_compensation, shareholder_vote_results, or auditor_change). The disclosure is material because it fundamentally alters the share structure and trading characteristics of the company's securities, affecting all shareholders' holdings and the stock's market presentation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
SciSparc's subsidiary NeuroThera Labs announced significant enrollment progress in a clinical trial for SCI-210, an autism spectrum disorder treatment, with 26 of 60 planned children enrolled in a double-blind, randomized, placebo-controlled study at Soroka Medical Center. This represents a material operational milestone in the company's drug development program reflecting advancement toward regulatory approval and commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.2
NeuroThera Labs announced its pursuit of FDA Orphan Drug Designation for SCI-110, a cannabinoid-based therapeutic for adult Tourette Syndrome, and engaged RK Strategies for government affairs support. The Orphan Drug Designation represents a material regulatory and operational milestone that could strengthen the product's market profile and advance the clinical development pathway.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-09-02
EX-99.1
This exhibit is a conversion agreement dated September 2, 2026, whereby Clearmind Medicine converts outstanding convertible notes totaling $696,079.50 into common shares at an agreed conversion price of $1.00 per share. The conversion results in issuance of approximately 696,079 common shares to accredited investors (L.I.A Pure Capital Ltd. and Capitalink Ltd.), which is dilutive to existing shareholders. The agreement explicitly waives the original conversion price formula in the notes and amends the floor price, indicating a negotiated restructuring of the debt-to-equity conversion that would materially affect share count and ownership structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Item 3.02
ISQ Open Infrastructure Company LLC issued and sold $16.65 million in aggregate net consideration of unregistered equity securities across multiple share classes in Series I and Series II as of August 1, 2026, pursuant to Section 4(a)(2) and Regulation D/S exemptions.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 8.01
ISQ Open Infrastructure Company LLC acquired a new AI/edge colocation data center asset called Saragon in August 2026 as a material portfolio addition to its infrastructure investment operations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-02
EX-99.1
Scage Future received two Nasdaq deficiency notifications on August 27, 2026, advising that the Company no longer meets minimum Market Value of Listed Securities (MVLS) of $50 million and Market Value of Publicly Held Shares (MVPHS) of $15 million. The Company has been granted a 180-day compliance period through February 23, 2027, and faces potential delisting if it fails to regain compliance. The press release explicitly states that if compliance is not achieved, "the Company will receive written notification that its securities are subject to delisting," and notes that a deficiency indicator will be displayed on Nasdaq. This is a clear delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-09-02
Item 8.01
This Item 8.01 disclosure centers on preliminary shareholder redemption requests (22,171,711 Class A shares) in connection with a pending SPAC business combination with NorthStar. While the filing addresses a material M&A transaction (the Business Combination), the specific event disclosed here is the redemption request status and contingency on closing conditions, which does not fit cleanly into the ma_activity category (which covers entry, completion, or termination). The redemption mechanics and uncertainty about final proceeds are material to investors assessing the transaction's viability and post-closing capitalization, but the prose does not announce completion, termination, or a definitive change in the M&A status itself—only the interim redemption request tally pending closing.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 7.01
The disclosure announces the formation of a wholly owned subsidiary (Linkhome Technologies Inc.) and commencement of a preliminary evaluation of a potential AI computing infrastructure project in Europe involving up to 144 NVIDIA GB300 GPUs. This is a strategic operational initiative that could materially affect the company's business direction and capital allocation, though the project remains in early evaluation stages with no binding commitments or final board approval of the project itself. The event is operational/strategic in nature rather than fitting a specific named category.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-02
BTC Digital received a Nasdaq deficiency letter on August 27, 2026, for non-compliance with the Nasdaq Bid Price Rule (Rule 5550(a)(2)) due to closing bid prices below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until February 23, 2027, with explicit notice that failure to regain compliance could result in delisting. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-09-02
Item 1.01
Inflection Point Acquisition Corp. VIII consummated a $287.5 million IPO on August 31, 2026, issuing 28,750,000 units at $10.00 per unit, together with entry into multiple material definitive agreements (underwriting agreement, warrant agreement, investment management trust agreement, registration rights agreement, and private placement warrant purchase agreements). This capital-raising event and SPAC formation represents a material change of control structure and precursor to future business combinations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Item 3.02
Concurrent with the IPO, the company completed a private placement of 8,000,000 unregistered warrants to the Sponsor (5,000,000) and Representative (3,000,000) at $1.00 per warrant, generating $8,000,000 in gross proceeds. The warrants are exercisable into Class A ordinary shares at $11.50 per share and materially affect share ownership and voting power.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
On August 27, 2026, Steven Tannenbaum, William J. Liquori, and William Denkin were appointed to the board of directors in connection with the IPO, with assignments to the Audit and Compensation committees. The appointments establish the company's independent director governance structure at the time of its public offering.
View raw filing on EDGAR →
6-K
Going Concern
confidence 95%
filed 2026-09-02
The 6-K body explicitly discloses material uncertainty regarding the Company's ability to continue as a going concern. The filing states the Company "has been subject to material uncertainty regarding its ability to continue as a going concern" and that "the unavailability of the financial support previously relied upon by the Company and the Petition represent a material adverse development in the Company's liquidity position and have significantly increased the previously disclosed material uncertainty regarding the Company's ability to satisfy its obligations as they become due and to continue as a going concern." This is a quintessential going-concern disclosure.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-09-02
EX-99.1
Fort Technology announces the grant of 102,857 restricted share units (RSUs) pursuant to its Omnibus Equity Incentive Plan, including 30,000 RSUs to an officer and 72,857 RSUs to consultants. This is a compensatory arrangement disclosure under the equity incentive plan framework, with specific vesting schedules tied to named recipients. The grant to an officer and the material size of the aggregate grant (representing approximately 5.4% of the Plan's 1.9M share reserve) make this material to investors assessing executive compensation and potential dilution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
The filing discloses the appointment of three new independent directors (Mark Schwartz, Kimi L. Ellen, and Dante W. Robinson) to Solidion's Board, increasing board size from four to seven members. The appointments are material as they strengthen the company's financial and governance expertise, and critically, the Audit Committee appointments restore Nasdaq Rule 5605(c)(2)(A) compliance, which the company had previously lost. This is a significant governance event affecting board composition and committee structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
Item 3.01
Reborn Coffee received a notice from Nasdaq on August 27, 2026, stating that the Company no longer complies with Listing Rule 5250(c)(1) due to failure to file its Form 10-Q for the period ended June 30, 2026. The Company has 60 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within 180 days.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Corvex entered into a Securities Purchase Agreement on August 31, 2026, for a private placement of 3,904,970 common shares at $7.75 per share and 353.098 shares of Series D Preferred Stock at $7,750 per share, generating approximately $33 million in gross proceeds. This is an unregistered sale of equity securities under Section 4(a)(2) and Regulation D, disclosed under Item 1.01 and Item 3.02, which is a classic dilutive issuance event. The filing explicitly states the securities are not registered and are being sold in reliance on the private placement exemption.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
Triller Group received notice from Nasdaq on August 27, 2026, that it failed to maintain the minimum market value of listed securities (MVLS) of $35 million required under Nasdaq Listing Rule 5550(b)(2), creating a deficiency that "could result in the delisting of the Company's securities from Nasdaq." The company has seven calendar days to submit a compliance plan. This is a textbook delisting-risk disclosure under Item 3.01, and the filing explicitly states the company no longer satisfies a continued listing requirement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 90%
filed 2026-09-02
Item 1.01
NKGen Biotech entered into a Fourth Amendment to its Secured Convertible Loan Agreement on August 5, 2026, creating Additional Loan #4 of $1,050,500 principal ($955,000 net proceeds), documented by a new Secured Convertible Promissory Note bearing interest and convertible into common stock at $0.08/share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Item 3.02
NKGen Biotech issued unregistered equity securities including Consideration Shares in installments, a convertible note (Additional Note #4) convertible at $0.08/share, and a warrant (Additional Warrant #4) exercisable at $0.08/share, all issued under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-02
Item 1.01
VenHub Global entered into an Equity Purchase Agreement with Euphoria Capital providing for up to $100 million in committed purchases of common stock, with an immediate issuance of 800,000 commitment shares and potential for up to 18,278,571 additional shares to be sold via put notices at 97% of VWAP. The unregistered sales are offered in reliance on Section 4(a)(2) and Rule 506(b) exemptions, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
VenHub Global received formal notification from Nasdaq on September 1, 2026, that it has failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Marketplace Rule 5450(a)(1). The company has 180 calendar days until March 1, 2027, to regain compliance or faces potential delisting.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-02
EX-99.1
This press release announces the results of an Extraordinary General Meeting held on September 1, 2026, where shareholders voted on and approved two proposals: (1) a 20-for-1 share consolidation affecting all classes of ordinary shares, effective September 15, 2026, and (2) adoption of amended memorandum and articles of association. The disclosure directly reports shareholder vote outcomes on material corporate actions, fitting the shareholder_vote_results taxonomy. The share consolidation is material to investors as it fundamentally alters share structure and par value.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 1.01
NorthStrive Biosciences (PMGC subsidiary) entered into a First Amendment to its Development and License Agreement with Yuva Biosciences on August 27, 2026, formalizing a three-phase Expansion Program to advance four AI-discovered compounds toward lead compound nomination in Cardiac Diseases and Obesity. The amendment updates program scope, IP framework, field of use definitions, financial terms, and grants a right of first refusal across the cardiometabolic field.
View raw filing on EDGAR →
6-K
Shareholder vote
confidence 95%
filed 2026-09-02
The 6-K discloses results of an extraordinary general meeting of shareholders held on September 2, 2026, at which shareholders voted on five proposals. All proposals were approved by overwhelming majorities, including ratification of a 50-for-1 share consolidation already effected on June 11, 2026, adoption of amended articles of association, approval of a new 16-for-1 share consolidation contingent on stock price performance, and related governance matters. This is a classic shareholder_vote_results disclosure reporting the outcomes and voting tallies from a shareholder meeting.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-02
Item 3.02
This Item 3.02 disclosure centers on the completion of a material acquisition: SoundHound AI's merger with LivePerson, approved by LivePerson stockholders on September 2, 2026. The filing describes the Amended and Restated Merger Agreement (dated July 2, 2026), the two-step merger structure, the Notes Restructuring Transactions, and the per-share merger consideration (0.4673 shares of Class A Common Stock plus $3.31 cash). While Item 3.02 typically covers unregistered equity issuances, the substance of this disclosure is the consummation of a transformative M&A transaction, not merely an equity sale. The merger satisfies all remaining closing conditions and the parties expect to proceed immediately.
View raw filing on EDGAR →
8-K
Other material
confidence 45%
filed 2026-09-02
Item 8.01
This Item 8.01 disclosure reports the completion of JATT III's IPO (6.9M shares at $10/share for $69M gross proceeds) and simultaneous private placement (234K shares for $2.34M), with $69M deposited in trust. While the IPO itself is a capital-raising event, it does not fit neatly into the standard taxonomy: it is neither a debt issuance, dilutive equity issuance (which typically refers to unregistered private placements), nor a traditional M&A or operational event. The disclosure is material to investors but the event type remains ambiguous—it is a registered public offering by a blank-check SPAC, which is a distinct capital structure event not explicitly covered by the taxonomy.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-09-02
The filing discloses a 1-for-20 reverse stock split of BioRestorative Therapies' common stock, approved by the Board of Directors on August 27, 2026, and effective September 7, 2026. This is a material modification to the rights and structure of the company's securities (Item 3.03), reducing outstanding shares from approximately 27.6 million to 1.4 million and authorized shares from 1.5 billion to 75 million. While reverse splits are governance/capital structure events rather than operational or financial events in the traditional sense, this is a material corporate action affecting all shareholders' share counts and trading mechanics, warranting classification as a governance matter that does not fit a more specific category.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
This press release announces the procurement of over 2,000 tons of raw materials and the underway installation of smelting equipment for a new metals recovery production line, with expected production before year-end 2026. The disclosure represents a material operational milestone—expansion into new waste-processing categories (electronic sludge, copper sludge, nickel sludge) and a new revenue stream—but does not fit the discrete event categories (no M&A, no financing, no impairment, no restructuring charge). It is clearly operational and strategic in nature, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-02
EX-99.1
Scienjoy announced entry into a sale and purchase agreement to acquire a 29.9% stake in Leader Education Limited for HK$102.69 million (approximately US$13.1 million) through its wholly-owned subsidiary. This is a material acquisition of a significant equity stake in a Chinese higher education service provider, disclosed as a strategic investment with integration of AI and technology capabilities. The transaction is subject to customary closing conditions and represents a discrete M&A event requiring disclosure under Item 1.01 or 2.01 equivalent.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-09-02
Item 1.01
Andretti Acquisition Corp. II entered into material definitive non-redemption agreements with multiple investors on September 1-2, 2026, whereby the Company and Sponsor agreed to issue up to 733,334 aggregate Pubco Shares in connection with a future initial business combination in exchange for investor commitments to not redeem 5.8 million Public Shares. These agreements are material to the SPAC's capital structure and the likelihood of completing a business combination, as they preserve trust account funds and represent binding commitments tied to the consummation of an acquisition. While technically a financing/capital arrangement rather than a traditional M&A transaction, the agreements are disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and directly facilitate the Company's ability to pursue and close a business combination.
View raw filing on EDGAR →
8-K
M&A activity
confidence 88%
filed 2026-09-02
Item 1.01
Ribbon Acquisition Corp. entered into multiple material definitive agreements (Forward Purchase Agreement, Subscription Agreement, Standby Equity Purchase Agreement, and Convertible Promissory Note) in connection with a previously announced business combination among Ribbon, PubCo, DRC Merger Inc., and DRC Medicine Ltd., committing up to $100 million in equity financing and establishing complex post-closing investment terms.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-02
EX-99.1
This is a news release in which Aurora Cannabis's Board unanimously recommends shareholders REJECT Curaleaf's unsolicited take-over bid. The disclosure addresses a hostile acquisition attempt—a material M&A activity—and includes the Board's formal recommendation against the transaction, financial advisor opinions on valuation, and detailed analysis of risks to shareholders. The filing of a Directors' Circular and establishment of a special committee of independent directors further confirm this is a significant M&A event requiring shareholder action.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-02
The filing discloses that the Board of Directors approved the election of Benjamin Steinbruch as Chairman of the Board and that Fabio Schvartsman will assume the position of Chief Executive Officer (CEO) effective September 3, 2026. These are material executive appointments at the highest levels of the company. The disclosure is labeled "MATERIAL FACT" and filed as a 6-K, indicating the registrant itself considers this material to investors.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
The exhibit announces time charter contract extensions for two feeder containerships (M/V Joanna and M/V Aegean Express) at significantly higher rates than current contracts, expected to generate approximately $24 million of EBITDA over the minimum contracted period and materially improve charter coverage for 2026–2028. This is a material operational and commercial milestone for a shipping company, representing secured revenue and improved liquidity, but does not fit the specific event categories (it is neither a discrete M&A transaction, a debt issuance, nor a workforce action); it is best classified as a material operational/commercial contract event.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-09-02
Item 8.01
The Board approved a new share repurchase authorization for up to 482,500 shares through September 1, 2027, replacing the prior July 2025 authorization. Share repurchase programs are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs" alongside dividends and distributions. The authorization is material to investors as it signals capital allocation policy and shareholder returns.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-02
Item 2.02
Phreesia announced its fiscal second quarter ended July 31, 2026 financial results via press release and stakeholder letter on September 2, 2026. The disclosure includes key metrics (revenue of $129.5 million, up 10% YoY; net income of $1.9 million; Adjusted EBITDA of $32.9 million), forward guidance for fiscal 2027 (revenue $510–$520 million, Adjusted EBITDA $125–$135 million), and operational updates including a restructuring plan. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 94%
filed 2026-09-02
Item 1.01
NXP B.V. entered into a $250 million unsecured senior loan facility agreement with the European Investment Bank on September 1, 2026, creating a new direct financial obligation with a six-year maximum tenor, guaranteed by the parent company and subsidiaries, to fund capital expansion of semiconductor manufacturing capacity in Malaysia.
View raw filing on EDGAR →